Delcath Systems highlights clinical program presentations at ESMO Congress 2026 and independent data on liver-dominant metastatic uveal melanoma

DCTH•2026-10-19

Delcath Systems highlighted clinical program presentations at ESMO Congress 2026 and independent data on percutaneous hepatic perfusion in liver-dominant metastatic uveal melanoma.

Delcath Systems highlights clinical program presentations at ESMO Congress 2026 and independent data on liver-dominant metastatic uveal melanoma

Related News

Nexpu prices $28 million private placement of 40 million units at $0.70 each

Glenbrook Capital Management reports acquisition of $706,056.77 in SenesTech common shares

Dorchester Minerals agrees to acquire 4,300 net royalty acres in North Dakota

GBank Financial Holdings updates financial calendar

Tradeweb bolsters US corporate bond offerings with nearly $2 billion Trumid deal